comparemela.com
Home
Live Updates
Kura Gains 17% Over Positive Preliminary Clinical Data From Phase 1 Trial Of Ziftomenib : comparemela.com
Kura Gains 17% Over Positive Preliminary Clinical Data From Phase 1 Trial Of Ziftomenib
Stock of Kura Oncology, Inc. (KURA) gained 15 percent on Tuesday morning after the company announced positive preliminary clinical data from phase 1 trial Of Ziftomenib.
Related Keywords
United Kingdom ,
British ,
,
England Prudential Regulation Authority ,
General Motors Co ,
New York Stock Exchange ,
Drug Administration ,
York Stock Exchange ,
Neptune Resources ,
Holdings Plc ,
General Motors ,
New York Stock ,
Prudential Regulation Authority ,
Cytarabine ,
Ura Oncology ,
Aunorubicin ,
Ziftomenib ,
Reliminary Clinical Data ,
comparemela.com © 2020. All Rights Reserved.